Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Hepatol ; 50(6): 1202-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19376604

ABSTRACT

BACKGROUND/AIMS: Vitamin D receptor (VDR) agonists have recently been identified as potent immunomodulators capable of inhibiting Th1-mediated immune response, leading us to consider the hypothesis that functional VDR polymorphisms might contribute to enhanced risk for developing primary biliary cirrhosis (PBC), a Th1-mediated autoimmune disease. In the current study, we aimed at elucidating the genetic association of VDR polymorphisms with susceptibility to PBC in Japanese and Italian populations. METHODS: We enrolled 334 PBC patients (195 Japanese and 139 Italians), as well as 334 age- and sex-matched controls (179 Japanese and 156 Italians). VDR genotyping was performed by PCR-RFLP, using BsmI, ApaI and TaqI endonucleases. RESULTS: The genotype BB of BsmI polymorphism was significantly associated with PBC (OR = 1.80 [95% CI; 1.19-2.73], p = 0.005). The association of the genotype BB was observed in Japanese (OR = 13.77, p = 0.001), and Italians (OR = 1.83, p = 0.019), respectively, although not significant in Italians after Bonferroni correction. The frequency of the B allele at the BsmI polymorphism was significantly higher in PBC patients (OR = 1.27 [95% CI; 1.02-1.59], p = 0.040). CONCLUSIONS: The genotype 'BB' as well as 'B' allele at BsmI polymorphism of the VDR gene contribute to the risk of PBC development.


Subject(s)
Liver Cirrhosis, Biliary/genetics , Polymorphism, Restriction Fragment Length , Receptors, Calcitriol/genetics , Aged , Alleles , Autoimmune Diseases/etiology , Autoimmune Diseases/genetics , Autoimmune Diseases/immunology , Base Sequence , Case-Control Studies , DNA Primers/genetics , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Humans , Italy , Japan , Liver Cirrhosis, Biliary/etiology , Liver Cirrhosis, Biliary/immunology , Male , Middle Aged , Receptors, Calcitriol/immunology , Th1 Cells/immunology
2.
Ann N Y Acad Sci ; 1107: 259-70, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17804554

ABSTRACT

It still remains unclear how antimitochondrial autoantibodies (AMA) are involved with immunopathogenesis of primary biliary cirrhosis (PBC). We have suggested the potential role of IgA-AMA in damage to epithelial cells in PBC. In the current study, we investigated whether IgA-AMA were detectable in sera and saliva of PBC patients, to examine the association between detectable IgA-type autoantibodies in sera or saliva and progression of liver diseases. Fifty-three patients with PBC were enrolled, and IgA-AMA in sera and saliva were sought by immunoblotting using pork heart mitochondria as antigens. The progression of PBC was determined as Scheuer's classification consisting of four histological stages. We found IgA-AMA, IgA-anti-PDC-E2, and IgA-anti-E3BP in 43/53 (81%), 37/53 (70%), and 35/53 (66%) sera of patients with PBC, but none of controls. The progression of PBC was statistically associated with presence of IgA-anti-PDC-E2 (P = 0.0124), but neither with IgA-AMA (P = 0.1296) nor anti-IgA-E3BP (P = 0.5973). In saliva, detectable IgA-AMA, IgA-anti-PDC-E2, and IgA-anti-E3BP were noted in 12/26 (46%), 6/26 (23%), and 11/26 (42%), respectively. Detection of IgA-anti-PDC-E2 was strongly associated with progression of PBC (P = 0.0002), whereas detection of IgA-AMA and IgA-anti-E3BP were not associated (P = 0.2145 and P = 0.5118). The current findings suggest that the presence of IgA-anti-PDC-E2 in sera or saliva might be associated with progression of PBC, although a prospective study with PBC patients with detectable IgA-anti-PDC-E2 at early stages will be required to conclude the contribution of IgA-anti-PDC-E2 to the progression of PBC.


Subject(s)
Immunoglobulin A, Secretory/immunology , Immunoglobulin A/immunology , Immunoglobulin A/metabolism , Liver Cirrhosis, Biliary/immunology , Liver Cirrhosis, Biliary/pathology , Mitochondria/immunology , Saliva/immunology , Disease Progression , Female , Humans , Liver Cirrhosis, Biliary/metabolism , Male , Middle Aged , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/immunology
3.
J Gastroenterol Hepatol ; 21(9): 1448-54, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16911691

ABSTRACT

BACKGROUND AND AIM: Antimitochondrial autoantibodies (AMA) are known to be a hallmark of primary biliary cirrhosis, and it has been suggested that AMA play a crucial role in generating biliary changes. Biliary tract lesions are not uncommon in patients with autoimmune hepatitis (AIH) and previous works have demonstrated that AMA are occasionally detectable in sera of patients with AIH. Therefore, the role of AMA as a cause of bile duct lesions in AIH livers should be addressed. The aim of the present study was to determine whether the presence of AMA is associated with clinical features, especially the occurrence of bile duct lesions, in patients with AIH. METHODS: Forty-one patients diagnosed as having AIH according to the revised scoring system of the International Autoimmune Hepatitis Group were enrolled in this study. Clinical data were retrospectively reviewed, and histological findings of the liver were investigated. AMA reactivity was determined by immunoblotting using beef heart mitochondria as antigens. RESULTS: Although not found in any enrolled patient by conventional indirect immunofluorescence, AMA were detectable in 14 out of 41 patients (34%). Clinical parameters including biochemistry, autoantibody profile, and responses to treatment were similar irrespective of AMA status. Bile duct lesions were noted in 14/14 (100%) and 23/27 (85%) of AMA-positive and -negative patients with AIH, respectively (P = 0.134). There was no statistically significant difference in the grade of inflammation or stage of fibrosis between the two groups. CONCLUSION: Antimitochondrial autoantibodies were found to be present in sera of patients with AIH more frequently than expected, even at very low titer. However, clinical features and histological findings of AIH were not influenced by the AMA status.


Subject(s)
Autoantibodies/blood , Hepatitis, Autoimmune/blood , Hepatitis, Autoimmune/immunology , Mitochondria, Heart/immunology , Animals , Anti-Inflammatory Agents/therapeutic use , Bile Ducts/cytology , Bile Ducts/pathology , Cattle , Cholagogues and Choleretics/therapeutic use , Female , Fibrosis/immunology , Fibrosis/pathology , Hepatitis, Autoimmune/pathology , Hepatitis, Autoimmune/therapy , Humans , Liver/cytology , Liver/pathology , Male , Middle Aged , Prednisolone/therapeutic use , Ursodeoxycholic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...